| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c2741412abe407fb173b5d21cca3187f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4833
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0047
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L26-0057
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08L89-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0644
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 |
| filingDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccefde3c030656c0697f5c542bb9cbe6 |
| publicationDate |
2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113423420-A |
| titleOfInvention |
Wound treatment gel obtainable by combining platelet rich plasma with autologous derived thrombin |
| abstract |
The present invention provides a method of making a wound treatment composition, wherein the method comprises: i) fractionating a whole blood sample into a plurality of samples including a Platelet Rich Plasma (PRP) sample, a Platelet Poor Plasma (PPP) sample, and a red blood cell sample, wherein the PRP sample has a hematocrit level of 1-10%; ii) processing a portion of the PPP and/or PRP sample to promote cleavage of the autologous prothrombin present in the PPP and/or PRP to produce autologous thrombin; and iii) combining the PRP sample with a portion of the PPP sample and a portion of the thrombin generated in step (ii) to produce the wound treatment composition; wherein step ii) is carried out at a temperature below 15 ℃. In preferred embodiments, the PRP has a hematocrit level of 2% or 8%. Wound treatment compositions produced by the methods are also provided as compositions for treating chronic and acute wounds. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115068691-A |
| priorityDate |
2018-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |